SEC Form 4 · accession 0001376043-26-000010
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy Coughlin
Director
Period of report
Jun 12, 2026
Accepted (ET)
Jun 16, 2026 · 4:46 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 12, 2026 | M | 10,000 | $26.52 | A | 66,250 | D | |
| Common StockF2 | Jun 12, 2026 | S | 10,000 | $50.0747 | D | 56,250 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $26.52 | Jun 12, 2026 | M | 10,000 | D | — | May 8, 2028 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F2The weighted average sale price for the transaction reported was $50.0747, and the range of prices were between $50.00 and $50.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F3The stock option is fully vested and exercisable.